Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11074881 | 0.71 | — | — | |
| SCHEMBL2123662 | 0.69 | — | — | |
| SCHEMBL1663629 | 0.69 | — | — | |
| SCHEMBL1285864 | 0.69 | — | — | |
| SCHEMBL818918 | 0.69 | — | — | |
| SCHEMBL18423144 | 0.69 | — | — | |
| SCHEMBL18105103 | 0.69 | — | — | |
| SCHEMBL7865367 | 0.67 | — | — | |
| SCHEMBL10293770 | 0.67 | — | — | |
| SCHEMBL29037143 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2024-02-29 | — | — | US | disclosed |
| EP-4255904-A2 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022117882-A2 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2022-06-09 | — | — | WO | disclosed |
| US-20090247680-A1 | ADHESION PROMOTING ADDITIVE | AVERY DENNISON CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
| EP-2024440-A2 | ADHESION PROMOTING ADDITIVE | AVERY DENNISON CORPORATION (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007146603-A2 | ADHESION PROMOTING ADDITIVE | AVERY DENNISON CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
| US-5342767-A | Transferring a hydride ion from an R-configured alcohol to the pro-R face of nicotinamide adenine dinucleotide phosphate | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-08-30 | — | — | US | disclosed |
| US-5225339-A | NADPH <--> NADP | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | DRD2 1709/4885DRD4 4364/4885DRD3 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.